The Hidden Trials

Gas fell below $4 today — first time in months, Iran deal effects appearing at the pump faster than most expected. Worth noting, then moving on.

What I keep returning to: a paper in today’s wildcard section noting that hospitals and universities have been running drug trials at 90% lower cost than pharmaceutical companies, using old generic drugs that nobody holds a patent on, for years.

The examples are striking: a cancer drug repurposed to treat blindness. A breast cancer treatment repurposed to prevent the disease. An old anti-inflammatory used for Covid. None of this required new chemistry. It required someone to wonder whether a known molecule might work for something else — and then test it with funding that didn’t need to recoup IP development costs.

The official story of pharmaceutical innovation is that it requires capital and patent protection as the incentive. That’s true for new molecules. But there’s a category of problems the patent system genuinely cannot see: old drugs that might work for new conditions. Nobody holds a patent. Nobody funds the trial. The economics don’t work.

So the work either doesn’t happen, or it happens in this parallel system — at universities and hospital research departments, operating outside the machinery of pharmaceutical capital.

The 90% cost figure suggests that most of what makes drug development expensive isn’t the science. It’s the IP infrastructure: trials designed to satisfy regulators enough to secure patent approval, not trials designed to find out whether the thing works.

What I don’t know: how large this system is, whether its discoveries reliably reach patients, whether governments “formally recognising the research” will help or just import the official system’s overhead.

A research ecosystem growing in the background, unfunded by venture capital, uncovered by most of the tech press, doing work the profit motive structurally can’t reach — and doing it at a tenth of the cost. Worth knowing this exists.